Table 1 Patients’ characteristics.
% | ||
|---|---|---|
Age | ||
Median | 69 | Range 21–88 |
Gender | ||
Male | 59 | 79.7 |
Female | 15 | 20.3 |
ECOG PS | ||
0 | 21 | 28.4 |
1 | 43 | 58.1 |
> 2 | 10 | 13.5 |
Primary tumor site | ||
Oral cavity | 27 | 36.5 |
Nasopharynx | 5 | 6.8 |
Oropharynx | 7 (p16 + n = 4) | 9.5 |
Hypopharynx | 24 | 32.4 |
Larynx | 3 | 4.1 |
Unknown | 3 | 4.1 |
Others | 5 | 6.8 |
CPS | ||
> 20 | 38 | 51.4 |
1–19 | 22 | 29.7 |
< 1 | 6 | 8.1 |
NE | 8 | 10.8 |
BMI | ||
Median | 20.18 | Range 14.36–34.92 |
Metastatic site | ||
Lung | 27 | 36.5 |
Liver | 3 | 4.1 |
Lymphnode | 38 | 51.4 |
Bone | 11 | 14.9 |
Locoregional | 17 | 23 |
Regimen | ||
Pembrolizumab + chemotherapy | 46 | 62.2 |
Pembrolizumab alone | 28 | 37.8 |
